Zeria Pharmaceutical has patented a method for preparing solid dosage forms for oral administration, containing antibodies and functional fragments, with immediate and sustained release capabilities. The method involves layering an inert core with drug coatings and applying delayed release coatings. These dosage forms are used for topical treatment in the gastrointestinal tract. GlobalData’s report on Zeria Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Zeria Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zeria Pharmaceutical's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Method for preparing solid oral dosage forms with antibodies coating
A recently granted patent (Publication Number: US11826470B2) outlines a method for preparing a solid dosage form suitable for oral administration. The method involves coating an inert core unit with a drug coating comprising at least one antibody or functional fragment, a buffer, and a polymeric binder through a series of steps. These steps include preparing an active agent coating liquid, layering the core unit with the liquid using spray coating, drying the wet layered unit, adding sustained release and delayed release coatings, and applying additional coatings as needed. The method ensures precise control over the composition and release of the active agent, making it suitable for immediate and delayed release formulations.
The patent further details specific parameters for the composition and process, such as the concentration of the antibody in the coating liquid, the selection of polymeric binders, and the temperature conditions during coating and drying. The method also includes the use of sustained release polymers and plasticizers to achieve the desired release profile. Additionally, the patent specifies the types of antibodies or functional fragments that can be used in the formulation, targeting various disease pathways. The resulting solid dosage form is intended for the treatment of gastrointestinal diseases, with controlled release mechanisms that target specific regions of the digestive tract. Overall, the patented method offers a comprehensive approach to formulating oral dosage forms with precise control over drug release and efficacy.
To know more about GlobalData’s detailed insights on Zeria Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
